Beyond the sarcomere: copper chelation in hypertrophic cardiomyopathy

“This trial suggests trientine may be a promising option for people with hypertrophic cardiomyopathy. People with more advanced disease seemed to benefit the most, but larger studies are needed to confirm this. There were few side effects, and the drug was generally well tolerated.”

“These findings provide the first evidence that targeting copper could open a new chapter in treating all patients with this condition.”

“These promising results offer hope to patients, demonstrating how trientine—a drug targeting copper metabolism—can treat this potentially fatal inherited heart condition. Once again, this shows how MRC and NIHR's key partnership can drive life-changing research. Together, we are addressing complex clinical challenges and translating cutting-edge ideas into evidence-based treatments as part of the government's mission for fewer lives to be lost to the biggest killers.”